Literature DB >> 8336824

Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A.

M Poncelet1, V Santucci, R Paul, C Gueudet, S Lavastre, J Guitard, R Steinberg, J P Terranova, J C Brelière, P Soubrié.   

Abstract

The biochemical, electrophysiological and behavioural effects of SR 31742A, a novel and selective ligand of sigma sites in brain, labelled with (+)-[3H]3PPP (Ki = 5.3 +/- 0.3 nM), were investigated in rodents and compared with those of DA antagonists having (haloperidol) or not (spiroperidol) a high affinity for sigma sites. Like haloperidol but unlike spiroperidol, SR 31742A, (ED50 = 0.065 mg/kg, i.p., and 0.21 mg/kg, p.o.) antagonized sigma-dependent turning behaviour in mice and inhibited (0.5 mg/kg, i.v.) the spontaneous firing of hippocampal (CA3) neurones in urethane-anaesthetized rats. In chloral hydrate-anaesthetized rats, like classical antipsychotic compounds, SR 31742A (0.625-5 mg/kg, i.p.) increased the number of spontaneously active A9 and A10 DA cells after single administration and produced an opposite effect after repeated injections. The drug SR 31742A reduced (2.5, 5, 10 mg/kg, i.p.) the hyperactivity elicited by various drugs including that produced by injection of (+)-amphetamine into the nucleus accumbens and impaired avoidance responses at doses (5, 10 mg/kg, i.p.), sparing escape behaviour. SR 31742A lacked affinity for DA receptors and neither did the compound induce catalepsy nor antagonize such effects elicited by apomorphine as climbing, hypothermia, stereotypy or the inhibition of firing of DA neurones. SR 31742A did not affect the basal metabolism of DA but at 10 mg/kg (i.p.) it significantly reduced the amphetamine-induced rise in levels of 3-MT in the striatum of mice. Together, these results indicate a modulatory role for sigma sites upon the activity of hippocampal and DA systems and that sigma ligands exert effects, which suggest antipsychotic potential.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8336824     DOI: 10.1016/0028-3908(93)90057-a

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Turning behavior induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists.

Authors:  M Poncelet; C Gueudet; D Gully; P Soubrié; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

3.  Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats.

Authors:  M Poncelet; J Souilhac; C Gueudet; J P Terranova; D Gully; G Le Fur; P Soubrié
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

4.  Dopamine-1 receptor agonist, but not cocaine, modulates sigma(1) gene expression in SVG cells.

Authors:  Oren Ben-Ami; Noa Kinor; Alexander Perelman; Gal Yadid
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 2.866

5.  Behavioral Effects of a Potential Novel TAAR1 Antagonist.

Authors:  Vincent M Lam; Catharine A Mielnik; Corey Baimel; Pieter Beerepoot; Stefano Espinoza; Ilya Sukhanov; Wendy Horsfall; Raul R Gainetdinov; Stephanie L Borgland; Amy J Ramsey; Ali Salahpour
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

6.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.